Results

The initial literature search identified 1815 papers; four met the eligibility criteria. Three were randomized clinical trials and one was a phase II single-arm prospective cohort study. MEKi investigated included: pimasertib, selumetinib, trametinib, and binimetinib. A total of 680 patients were included in these studies, of which 416 were treated with a MEKi alone. All patients were treated for recurrent LGSOC. Objective response rates (ORR) to MEKi ranged from 12.1 to 26% and median progression-free survival (PFS) ranged from 7.2 to 13 months.

Conclusion

While one study demonstrated significantly improved efficacy of a MEKi over physician-choice systemic therapy in the treatment of recurrent LGSC, another did not show significant benefit. Two additional studies did not compare MEKi to current traditional chemotherapy or hormonal therapies used in the management of LGSC, limiting their clinical relevance. Mutation profiles within the tumors may affect the ORR to various MEKi. Further prospective and randomized trials are needed to determine the efficacy of MEKi in treating LGSC.

2022-RA-1133-ESGO

UTILITY VALUES IN PROC

1Anupriya Mehra, 2Nikhila Indukuri, 3Mihaela Musat, 4Gordon Chavez, 5Christina Proescholdt, 6Ascension Saint Joseph Hospital Chicago, Chicago, IL; 7Novocure Ltd, New York, NY; 8Cytel Inc., Cambridge, MA

Introduction/Background

Platinum-resistant ovarian cancer (PROC) is associated with a substantial humanistic and economic burden due to disease symptoms, treatment-related side effects and costs. Cost-utility analyses that inform healthcare decision-makers require a set of health state utility values (HSUVs). As part of a systematic literature review (SLR), published evidence of HSUVs associated with PROC were described.

Methodology

The scope of the SLR was defined using the Patient population, Intervention, Comparators, Outcomes and Study design (PICOS) statement, and performed using pre-defined search terms in accordance with PRISMA guidelines. Key biomedical literature databases (Medical Literature Analysis and Retrieval System Online [MEDLINE®] and Excerpta Medica Database [Embase®]), EconLit and Cochrane were searched for records dated up to July 6, 2021. Relevant congresses (2017–2021), previous health technology assessment submissions, and previously conducted SLRs were also searched to capture relevant data.

Results

Out of 34 studies from the SLR, 17 publications reporting HSUVs were identified. Of these, nine studies gathered EQ-5D values directly from ovarian cancer patients, four mapped EQ-5D HSUVs from FACT-O or FACT-G values, three studies mapped utility values from other solid tumor indications and one modeled EQ-5D HSUVs using Bayesian regression from patient registry data. HSUVs were relatively high at pre-progression (range 0.610 to 0.718) while patients without residual disease (RD), were eligible if they had response following platinum-based chemotherapy, were not eligible for bevacizumab, and lacked a mutation.

Conclusion

HSUVs for each line of therapy showed considerable heterogeneity, likely due to variability of data sources and differences in patient populations. Careful deliberation should be taken when conducting cost-utility analyses in patients with ovarian cancer.

2022-RA-1134-ESGO

FIRST REAL-LIFE DATA ON NIRAPARIB MAINTENANCE IN NEWLY-DIAGNOSED ADVANCED OVARIAN CANCER: A DESCRIPTIVE ANALYSIS OF THE TEMPORARY AUTHORISATION FOR USE (ATU) COHORT

1Thibault de la Motte Rouge, 2Frédéric Selle, 3Maria Klouy, 4Jean-David Fumet, 5Jean-Sébastien Frenel, 6Johanna Wasserman, 7Rémy Langiller, 8Anne Fages, 9Virginie Jacquemin, 10Nadka El Mouldin, 11Leila Haddad, 12Christophe Tessler, 13Philippe Foilana, 14Dominique Berton, 15Anne Floquet, 16Karine Prulière, 17Patricia Pautier, 18Département d’Oncologie Médicale, Centre Eugène-Marquis, Rennes, France; 19Département de Medical Oncology, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France; 20Département de Medical Oncology, Gustave Roussy, Villejuif, France; 21Département Oncologie Médicale, Centre Georges-François Lederc, Dijon, France; 22Département of Medical Oncology, Institut de Cancérologie de l’Ouest, Saint-Herblain, France; 23Département de Medical Oncology, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France; 24Département d’Oncologie Médicale, Centre Antoine Lacassagne, Nice, France; 25Département de Medical Oncology, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France; 26Département d’Oncologie Médicale, Centre Antoine Lacassagne, Nice, France; 27Département de Medical Oncology, Centre Georges-François Lederc, Dijon, France; 28Département d’Oncologie Médicale, Centre Antoine Lacassagne, Nice, France; 29Pharmacovigilance and Medical Quality Oncology, GSK, Paris, France; 30Medical Affairs Oncology, GSK, Paris, France; 31Medical Affairs Oncology, GSK, Paris, France; 32Medical Affairs Oncology, GSK, Paris, France; 33Medical Affairs Oncology, GSK, Paris, France; 34Medical Affairs Oncology, GSK, Paris, France; 35Medical Affairs Oncology, GSK, Paris, France; 36Medical Affairs Oncology, GSK, Paris, France; 37Medical Affairs Oncology, GSK, Paris, France; 38Medical Affairs Oncology, GSK, Paris, France; 39Medical Affairs Oncology, GSK, Paris, France; 40Medical Affairs Oncology, GSK, Paris, France; 41Medical Affairs Oncology, GSK, Paris, France; 42Medical Affairs Oncology, GSK, Paris, France; 43Medical Affairs Oncology, GSK, Paris, France; 44Medical Affairs Oncology, GSK, Paris, France; 45Medical Affairs Oncology, GSK, Paris, France; 46Medical Affairs Oncology, GSK, Paris, France; 47Medical Affairs Oncology, GSK, Paris, France; 48Medical Affairs Oncology, GSK, Paris, France; 49Medical Affairs Oncology, GSK, Paris, France; 50Medical Affairs Oncology, GSK, Paris, France; 51Medical Affairs Oncology, GSK, Paris, France; 52Medical Affairs Oncology, GSK, Paris, France; 53Medical Affairs Oncology, GSK, Paris, France; 54Medical Affairs Oncology, GSK, Paris, France; 55Medical Affairs Oncology, GSK, Paris, France; 56Medical Affairs Oncology, GSK, Paris, France; 57Medical Affairs Oncology, GSK, Paris, France; 58Medical Affairs Oncology, GSK, Paris, France; 59Medical Affairs Oncology, GSK, Paris, France; 60Medical Affairs Oncology, GSK, Paris, France; 61Medical Affairs Oncology, GSK, Paris, France; 62Medical Affairs Oncology, GSK, Paris, France; 63Medical Affairs Oncology, GSK, Paris, France; 64Medical Affairs Oncology, GSK, Paris, France; 65Medical Affairs Oncology, GSK, Paris, France; 66Medical Affairs Oncology, GSK, Paris, France; 67Medical Affairs Oncology, GSK, Paris, France; 68Medical Affairs Oncology, GSK, Paris, France; 69Medical Affairs Oncology, GSK, Paris, France; 70Medical Affairs Oncology, GSK, Paris, France; 71Medical Affairs Oncology, GSK, Paris, France; 72Medical Affairs Oncology, GSK, Paris, France; 73Medical Affairs Oncology, GSK, Paris, France; 74Medical Affairs Oncology, GSK, Paris, France; 75Medical Affairs Oncology, GSK, Paris, France; 76Medical Affairs Oncology, GSK, Paris, France; 77Medical Affairs Oncology, GSK, Paris, France; 78Medical Affairs Oncology, GSK, Paris, France; 79Medical Affairs Oncology, GSK, Paris, France; 80Medical Affairs Oncology, GSK, Paris, France; 81Medical Affairs Oncology, GSK, Paris, France; 82Medical Affairs Oncology, GSK, Paris, France; 83Medical Affairs Oncology, GSK, Paris, France; 84Medical Affairs Oncology, GSK, Paris, France; 85Medical Affairs Oncology, GSK, Paris, France; 86Medical Affairs Oncology, GSK, Paris, France; 87Medical Affairs Oncology, GSK, Paris, France; 88Medical Affairs Oncology, GSK, Paris, France; 89Medical Affairs Oncology, GSK, Paris, France; 90Medical Affairs Oncology, GSK, Paris, France; 91Medical Affairs Oncology, GSK, Paris, France; 92Medical Affairs Oncology, GSK, Paris, France; 93Medical Affairs Oncology, GSK, Paris, France; 94Medical Affairs Oncology, GSK, Paris, France; 95Medical Affairs Oncology, GSK, Paris, France; 96Medical Affairs Oncology, GSK, Paris, France; 97Medical Affairs Oncology, GSK, Paris, France; 98Medical Affairs Oncology, GSK, Paris, France; 99Medical Affairs Oncology, GSK, Paris, France; 100Medical Affairs Oncology, GSK, Paris, France; 101Medical Affairs Oncology, GSK, Paris, France; 102Medical Affairs Oncology, GSK, Paris, France; 103Medical Affairs Oncology, GSK, Paris, France; 104Medical Affairs Oncology, GSK, Paris, France; 105Medical Affairs Oncology, GSK, Paris, France; 106Medical Affairs Oncology, GSK, Paris, France.

Introduction/Background

Niraparib is a PARP inhibitor approved in Europe as maintenance monotherapy in advanced ovarian cancer (aOC) after response to 1L platinum-based chemotherapy. PRIMA/ENGOT-ov26/GOG-3012 showed significant improvement in progression-free survival in aOC with niraparib versus placebo. An early access program (cohort [c] ATU) in France allowed real-world patients with newly-diagnosed aOC who had limited treatment options to receive 1L maintenance treatment with niraparib, when bevacizumab maintenance was not an option for BRCA wild-type patients.

Methodology

Patients with newly-diagnosed aOC, including patients without residual disease (RD), were eligible if they had response following platinum-based chemotherapy, were not eligible for bevacizumab, and lacked a BRCA mutation. Niraparib was administered orally (200/300 mg/day) by baseline weight and platelet count.

Results

From August 2020–March 2021, 67 oncologists from 55 hospitals completed evaluations for 82 patients with newly-diagnosed aOC; 73 met all eligibility criteria; 67 were exposed to niraparib. Baseline characteristics (table 1) showed...